Relationship Between Dyslipidaemia And Glycaemic Status In Patients With Type 2 Diabetes Mellitus
- Author:
Subashini C Thambiah Mbbs
;
Intan Nureslyna Samsudin
;
Elizabeth George
;
Siti Yazmin Zahari Sham
;
Huey Ming Lee
;
Mohd Azril Muhamad
;
Zanariah Hussein
;
Nurain Mohd Noor
;
Masni Mohamad
- Publication Type:Journal Article
- Keywords:
diabetic dyslipidaemia;
glycated haemoglobin (HbA1c);
type 2 diabetes mellitus (T2DM);
lipid parameters;
fasting blood glucose (FBG)
- From:The Malaysian Journal of Pathology
2016;38(2):123-130
- CountryMalaysia
- Language:English
-
Abstract:
The risk of coronary heart disease (CHD) is dramatically increased in diabetic patients due to their
atherogenic lipid profile. The severity of CHD in diabetic patients has been found to be directly
associated with glycated haemoglobin (HbA1c). According to the Malaysian Clinical Practice
Guidelines on diabetes mellitus (DM), HbA1c level less than 6.5% reduces the risk of microvascular
and macrovascular complications. Hence, this study aimed to determine the relationship between
dyslipidaemia and glycaemic status in patients with type 2 DM (T2DM) patients in Hospital
Putrajaya, a tertiary endocrine centre in Malaysia. This was a cross sectional, retrospective study of
214 T2DM patients with dyslipidaemia who had visited the endocrine clinic between January 2009
and December 2012. Significant correlations were found between fasting blood glucose (FBG) and
HbA1c with total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL),
non-high density lipoprotein cholesterol (non-HDL), LDL/HDL ratio and TC/HDL ratio; greater
correlation being with HbA1c than FBG. In patients with HbA1c ≥ 6.5%, TC, TG, non-HDL and
TC/HDL ratio were significantly higher than in patients with HbA1c < 6.5%. Non-HDL, LDL/HDL
ratio, TC/HDL ratio and HbA1c were significantly lower in patients on statin treatment than nontreated
patients (p<0.05). This significant association between glycaemic status and dyslipidaemia
emphasises the additional possible use of HbA1c as a biomarker for dyslipidaemia as well as a
potential indirect predictor of cardiovascular disease (CVD) risk in T2DM patients.
- Full text:P020161005026890126517.pdf
